Fig. 1
Quarterly Change in Proportions of First-line Use for Each Drug Class Over Study Observation Period. ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; Q, quarter
Fig. 1 | BMC Cancer
Quarterly Change in Proportions of First-line Use for Each Drug Class Over Study Observation Period. ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; Q, quarter